1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
(
- Contribution to journal › Article
- 2022
-
Mark
Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression
(
- Contribution to journal › Article
- 2017
-
Mark
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
(
- Contribution to journal › Article
- 2015
-
Mark
A novel Lin-CD34+CD38-integrin α2- bipotential megakaryocyte-erythrocyte progenitor population in human bone marrow.
(
- Contribution to journal › Article
- 2013
-
Mark
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
(
- Contribution to journal › Article
- 2012
-
Mark
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2010
-
Mark
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
(
- Contribution to journal › Article
-
Mark
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
(
- Contribution to journal › Article
- 2009
-
Mark
Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.
(
- Contribution to journal › Published meeting abstract